Replies to post #217021 on Biotech Values

[DewDiligence]

Chart of Mavyret’s uptake (blastoff):

$ENTA pic says all you need to know @DewDiligence pic.twitter.com/65jA06uHVc

— dough (@semodough) February 3, 2018

[DewDiligence]

ABBV/ENTA US HCV scripts/week ending 2/2/18 (IMS):

ABBV/ENTA’s new-patient share (NRx) reached 36.1%, the highest-ever level reported by IMS. (Almost all of ABBV/ENTA’s US patient share is now coming from Mavyret.) ABBV/ENTA’s total-patient share (TRx) reached 29.6%.

Actual Mavyret scripts for week ending 2/2/18:

NRx 988 (+4% vs prior week)
TRx 1713 (+7% vs prior week)